The Centers for Medicare & Medicaid Services acted against the advice of its advisory committee by making the long-sought decision to offer Medicare reimbursement of CT scanning as a means of lung cancer screening among heavy smokers, earning the praise of groups like the Lung Cancer Alliance.
U.K. researchers have hit upon a drug combination that appears to combat lung cancer by triggering self-destruction in tumor cells.
Cleveland Clinic scientists believe they have identified possible blood biomarkers that could help detect lung cancer, based on the alteration of metabolic processes that happens to patients with the disease at various stages.
St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.
Novartis is prepping new studies that will test how well three of its oncology drugs--the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia--do when combined with Bristol-Myers Squibb's PD-1 drug nivolumab in a joint attack on non-small cell lung cancer.
Veracyte plans to snatch up Allegro Diagnostics for $21 million, making a grab for greater size and that company's promising new lung cancer test.
Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.
Clovis Oncology has come out of the gate at ASCO with updated--and promising--data on its targeted lung cancer drug CO-1686, offering fresh evidence of its durability and effectiveness.
Researchers at the University of Colorado have developed a new database and pattern-matching algorithm that allows drug developers to evaluate drugs and drug combinations for purposes other than their FDA-approved use.
Earlier in the month AstraZeneca, the longtime poster child of R&D dysfunction, was reduced to making some bold--possibly ridiculous--sales projections on early-stage programs. Now their research teams are coming up with some hard numbers, and they look good.